NCT01258842

Bifidobacterium Lactis HN019 Supplementation for Prevention of Influenza Infection in Healthy Adults

Double-blind, Randomized, Placebo-controlled Trial of the Effects of Prophylactic Bifidobacterium Lactis HN019 Supplementation on the Incidence of Influenza Infection in Healthy Adults

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 426 (estimated)
• Sponsor: Fonterra Research Centre · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

To determine if prophylactic supplementation with B. lactis HN019 reduces the risk of developing physician- and laboratory-confirmed influenza infection at any time during the 12-week supplementation period.

Conditions

• Influenza

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Bifidobacterium lactis HN019	B. lactis HN019 (5 billion cfu / day) sachet, consumed once per day for 12 weeks
DIETARY_SUPPLEMENT	Placebo	Placebo sachet, consumed once per day for 12 weeks

Timeline

• Start date: 2010-12-01
• Primary completion: 2011-05-01
• Completion: 2011-05-01
• First posted: 2010-12-13
• Last updated: 2010-12-13

Locations

2 sites across 1 country: United States